VANCOUVER, BC – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of… Read More
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies VANCOUVER, BC – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation… Read More
Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell line development and cell culture services to accelerate and optimize biologics production. Asimov,… Read More
RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults Also known as temporal arteritis, GCA is the most… Read More
VANCOUVER, BC – Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, shared key findings from its latest mRNA-LNP therapeutic research during the 2025 World Vaccine Congress, held… Read More
